These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33168045)

  • 1. Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Chen NB; Li QW; Zhu ZF; Wang YM; Cheng ZJ; Hui ZG; Guo SP; He HQ; Wang B; Huang XY; Li JB; Guo JY; Hu N; Ai XL; Zhou Y; Wang DQ; Liu FJ; Xie CM; Qiu B; Liu H
    Radiat Oncol; 2020 Nov; 15(1):260. PubMed ID: 33168045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
    Pu Y; Zhang JX; Liu H; Appelbaum D; Meng J; Penney BC
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2079-2092. PubMed ID: 29882161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
    In Lee H; Kyung Choi E; Ssan Kim S; Seob Shin Y; Won Park J; Yeol Song S
    Radiother Oncol; 2024 Sep; 198():110383. PubMed ID: 38879129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non-small cell lung cancer.
    Chen X; Zhang W; Luo L; Fu S; Cao D; Su S; Li Q; Yang W; Geng Y; Lu B; Ouyang W
    Cancer Med; 2024 Sep; 13(17):e70221. PubMed ID: 39279741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy.
    Choi HS; Jeong BK; Jeong H; Lee YH; Ha IB; Song JH; Kang KM
    Radiat Oncol; 2017 Jul; 12(1):122. PubMed ID: 28732516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
    Ostheimer C; Mäurer M; Ebert N; Schmitt D; Krug D; Baumann R; Henkenberens C; Giordano FA; Sautter L; López G; Fleischmann DF; Niyazi M; Käsmann L; Kaul D; Thieme AH; Billiet C; Dobiasch S; Arnold CR; Oertel M; Haussmann J; Gauer T; Goy Y; Suess C; Ziegler S; Panje CM; Baues C; Trommer M; Skripcak T; Medenwald D
    Strahlenther Onkol; 2021 May; 197(5):385-395. PubMed ID: 33410959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
    De Petris L; Lax I; Sirzén F; Friesland S
    Med Oncol; 2005; 22(4):375-81. PubMed ID: 16260855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of K
    Wang D; Liu S; Fu J; Zhang P; Zheng S; Qiu B; Liu H; Ye Y; Guo J; Zhou Y; Jiang H; Yin S; He H; Xie C; Liu H
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38910009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modern induction chemotherapy before chemoradiation for bulky locally-advanced nonsmall cell lung cancer improves survival.
    Ahmed I; Ferro A; Baby R; Malhotra J; Cohler A; Langenfeld J; Aisner J; Zou W; Jabbour SK
    J Cancer Res Ther; 2016; 12(2):952-8. PubMed ID: 27461680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Warner A; Dahele M; Hu B; Palma DA; Senan S; Oberije C; Tsujino K; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; De Ruyck K; De Dios NR; Bradley JD; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):612-20. PubMed ID: 26867890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
    Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
    Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
    Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
    Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
    Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
    Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy.
    Topkan E; Kucuk A; Ozturk D; Ozkan EE; Besen AA; Pehlivan B; Selek U
    Can Respir J; 2024; 2024():2803044. PubMed ID: 38975012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
    Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
    Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
    He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
    Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
    Reymen B; Van Loon J; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1319-24. PubMed ID: 23200174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.